Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Roumell Again Reduces Position in Transcept Pharmaceuticals

Jim Roumell‘s hedge fund, Roumell Asset Management, in a new form 4 filed with the SEC, reported selling some shares of Transcept Pharmaceuticals Inc (NASDAQ:TSPT). In one transaction, Roumell sold 2,380 shares of Transcept at the price of $3.75 apiece. At the same time, the fund reduced its exposure in the company by another 10,410 shares that have been transferred to an investment adviser. On the whole, Roumell now holds an aggregate amount of some 2.27 million shares.

James Roumell

Last week, Roumell disclosed selling another 7,020 shares of Transcept.

Disclosure: none

Recommended Reading:

Christian Leone, Luxor Capital Increase Exposure in Hemisphere Media Group

RCS Capital Reveals 8.3% Stake in Investors Capital Holdings

3 Billionaire Buys You Should Know About